Due to the COVID-19 pandemic, events may be changed or cancelled.

Please contact the organisers for more details.

2021


Methodological issues in the design and analysis of global health trials

8 November 2021 10:00 – 11:00 GMT| Online event | TMRP and The Global Health Network
Multi-arm, parallel-group clinical trials are an efficient way of testing several new treatments, treatment regimens or doses. However, guidance on the requirement for statistical adjustment to control for multiple comparisons (type I error), where a shared control group is utilised, is unclear. Dr Sile Molly will talk about when such adjustment will be needed or not needed. The composite endpoints are commonly used in global health trials. The win ratio as a new method for examining composite endpoints has since been widely adopted in cardiovascular (CV) trials. Mr Con Ariti will provide an overview of the principles behind the win ratio and provides insights into how to implement the win ratio in trial design and reporting. Determination of gestational age at delivery is often required in global health trials involved pregnant women. Mr James Dodd will summarise and compare different methods for calculating gestational age at delivery.

Register here →

WEBINAR - ICU PANDEMIC PREPAREDNESS IN IRELAND NOVEL DESIGNS TO RAPIDLY DELIVER RESULTS TO THE BEDSIDE: INFLUENZA, COVID AND BEYOND

02 December 2021 | Online event | UCD Dublin
In an effort to improve our clinical trial response to a future pandemic, Prof. Nichol has been part of an EU FP7 program (PREPARE) which has been preparing for a global pandemic since 2015. As part of this effort the REMAP-CAP trial, a global adaptive platform trial, has determined that steroids, anticoagulation (in moderate disease) and IL-6 RA are beneficial in COVID-19 and many other therapies are not helpful hydroxychloroquine, lopinavir / ritinovir, convalescent plasma and anticoagulation in critically ill patients. Irish hospitals, investigators and patients have contributed to these findings and are randomising to many additional interventions. He is also part of the SPRINT-SARI observational study which has described the impact of COVID-19 in Ireland and globally.

Register here →

Australian Trials Methodology Conference

6-7th December 2021 | Online Event | Aus TriM
The organising committee warmly invite you to join us at our first Australian Trials Methodology Conference, which will take place fully online over the 6th and 7th of December 2021. The meeting program will showcase cutting-edge trial design and analysis approaches in a way that is thought-provoking yet still accessible to biostatisticians, methodologists and trialists (across any clinical discipline) alike.

Register here →

2022


Including random centre effects in design, analysis and presentation of multi-centre trials HRB-TMRN Webinar Series

13 January 2022 | 12:00 (GMT) | London School of Hygiene and Tropical Medicine
In large multicentre trials in diverse settings, there is uncertainty about the need to adjust for centre variation in design and analysis. A key distinction is the difference between variation in outcome (independent of treatment) and variation in treatment effect. Through re-analysis of the CRASH-2 trial (2010), this study clarifies when and how to use multi-level models for multicentre studies with binary outcomes.

Register here →

WEBINAR: Informed consent in cluster randomized trials: a guide for the perplexed

09 February 2022 | 13:00 GMT | Western University Canada
Charles Weijer is Professor of Medicine, Epidemiology & Biostatistics, and Philosophy at Western University in London, Canada. He is a leading expert in the ethics of randomized controlled trials. From 2008 to 2013 Charles co-led a collaboration that produced the first international ethics guidelines for cluster randomized trials. His current work explores ethical issues in pragmatic randomized controlled trials that evaluate health interventions in real-world conditions to better inform patients, health providers and health systems managers. Charles led the writing team for the World Health Organization guidance on “Ethical Considerations for Health Policy and Systems Research,” published in 2019. In 2020, he served on the WHO Working Group for Guidance on Human Challenge Studies in COVID-19. Charles held the Canada Research Chair in Bioethics from 2005 to 2019, and, in 2016, he was elected to the Royal Society of Canada.

Register here →

ICTMC 2022 →

3rd-6th October 2022 | Harrogate, UK | The 6th International Clinical Trials Methodology Conference 2022

Please visit our webinars page to access previous recordings and for the latest series.